jRCT2080224589已完成1 期
An open-label Phase 1 study of E7386 in subjects with advanced solid tumors including colorectal cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open(masking not used)
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •1.Subjects with a histological and/or cytological diagnosis of solid tumor must have any of the following tumor types:
- •Dose Escalation part: Subjects with advanced, unresectable, or recurrent solid tumor including CRC for which no alternative standard therapy or no effective therapy exists
- •Expansion Part 1:
- •Subjects with advanced, unresectable, or recurrent CRC in third- or later-line, Or subjects with other gastrointestinal tumors such as small bowel carcinoma and gastrointestinal neuroendocrine tumors after at least 1 prior systemic chemotherapy regimen upon discussion and agreement with the sponsor.
- •Expansion Part 2:
- •Subjects with advanced, unresectable, or recurrent solid tumors expected to be highly dependent on Wnt/beta-catenin signaling pathway as specified below, who have no standard therapy. Disease progression must be confirmed within the past 12 months.
- •Desmoid tumor
- •Solid pseudopapillary neoplasm (SPN) of pancreas
- •As for subjects with solid tumors below, gene mutations should be confirmed with Sponsor-approved assays.
- •Small bowel carcinoma with mutation of CTNNB1 or APC
- •Adrenocortical carcinoma (ACC) with mutation of CTNNB1, APC or ZNRF3
- •Solid tumors (except for CRC) with APC mutation in subjects diagnosed as familial adenomatous polyposis (FAP)
- •Hepatocellular carcinoma (HCC) with CTNNB1 gain-of-function mutation
- •Other types of solid tumors (except for CRC and HCC) harboring one or more Wnt-related gene mutations (e.g. APC, AXIN1, CTNNB1, RNF43, etc.) expected to be highly dependent on Wnt/beta-catenin signaling pathway based on emerging data may be enrolled upon consultation and agreement with the sponsor.
- •2.Dose escalation part: Subjects with CRC must consent to tumor biopsy and submit the archival tumor tissue if it is stored.
- •Expansion part 1: Subjects with accessible tumors must consent to tumor biopsy. Subjects with inaccessible tumors may be enrolled without a biopsy upon consultation and agreement by the sponsor. Subjects must consent to submit the archival tumor tissue if it is stored.
- •Expansion part 2: Subjects must consent to submit the archival tumor tissue if available. Desmoid tumor subjects with no results of sponsor-approved assays must consent to submit archival tumor tissue or tumor biopsy at Screening.
- •3.Life expectancy of >=12 weeks
- •4.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- •5.Japanese aged >=20 years at the time of informed consent in dose escalation part
- •Subjects aged >=20 years at the time of informed consent in expansion part 1
- •Subjects aged >=18 years at the time of informed consent in expansion part 2
- •6.All AEs due to previous anti-cancer therapy have either returned to Grade 0-1 except for alopecia and Grade 2 peripheral neuropathy (renal/bone marrow/liver function should meet the inclusion criteria).
- •7.Adequate washout period before study drug administration:
- •Chemotherapy and radiotherapy: 3 weeks or more
- •Any therapy with antibody: 4 weeks or more
- •Any investigational drug or device: 4 weeks or more
- •Blood/platelet transfusion or G-CSF: 2 weeks or more
- •8.Adequate renal function, bone marrow function, liver function and serum mineral level
- •9.At least one measurable lesion based on RECIST 1.1
- •10.Subjects must agree to take Vitamin D continuous supplementation as per local institutional guideline/ investigators clinical discretion when 25-hydroxyvitamin D levels less than 10 ng/mL.
- •11.Dose escalation part: Subjects must consent to skin biopsies from skin tissue that is tumor-free during the study.
- •Expansion part 1: At least 5 subjects in each dose level must consent to skin biopsies from skin tissue that is tumor-free during the study. Subjects may be enrolled without skin biopsies upon consultation and agreement by the sponsor.
- •Expansion part 2: Subjects must consent to skin biopsies from skin tissue that is tumor-free during the study in principle. Subjects may be enrolled without consent to skin biopsies upon consultation and agreement by the sponsor.
排除标准
- •1.Major surgery within 21 days prior to starting study drug
- •2.Known to be human immunodeficiency virus (HIV) positive
- •3.Active infection requiring systemic treatment
- •4.Diagnosed with meningeal carcinomatosis
- •5.Subjects with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.
- •6.Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.
- •7.Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the bioavailability of E
- •8.Any of the bone disease/conditions as follows;
- •Osteoporosis with T-score of < -3.0 at the left or right total hip, left or right femoral neck or lumbar spine (L1-L4) as determined by dual energy x-ray absorptiometry (DXA) scan. Subjects with T-score <-2.5 to -3.0 and no prior medical therapy for osteoporosis can only be included provided that treatment with a bisphosphonate (eg, zoledronic acid) or denosumab has been started at least 14 days prior to the first dose of study drug.
- •Metabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia
- •Symptomatic hypercalcemia requiring bisphosphonate therapy
- •History of any fracture within 6 months prior to starting study drug
- •Any condition requiring orthopedic intervention
- •Bone metastasis not being treated by bisphosphonate or denosumab. Subject may be included if treatment with bisphosphonate or denosumab have been started at least 14 days prior to the first dose of study drug. Subjects with previous solitary bone lesions controlled with radiotherapy are eligible
- •History of symptomatic vertebral fragility fracture or any fragility fracture of the hip, pelvis, wrist or other location (defined as any fracture without a history of trauma or because of a fall from standing height or less)
- •Moderate (25% to 40% decrease in the height of any vertebrae) or severe (>40% decrease in the height of any vertebrae) morphometric vertebral fracture at baseline
- •9.History of active malignancy (except for original disease, or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, carcinoma in-situ of the bladder or cervix, or early stage gastric/colorectal cancer) within the past 24 months prior to the first dose of study drug
- •10.Prior treatment with E7386
结局指标
主要结局
-
safety Dose Limiting Toxicity Adverse events, Serious Adverse events
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Phase 1 study of E7386 in subjects with advanced solid tumors including colorectal cancerSolid tumor, Colorectal cancer, Gastrointestinal tumor, Small bowel carcinoma, Desmoid tumo, Adrenocortical carcinoma, Solid pseudopapillary neoplasm of pancreasJPRN-jRCT2080224589Eisai Co., Ltd.70
招募中
1 期
A study of E7130 in participants with solid tumorsJPRN-jRCT2080223823Eisai Co., Ltd.95
未知
1 期
A Phase 1 Study of E7080 in Subjects With Solid Tumorsolid tumorJPRN-jRCT2080221345Eisai Co., Ltd.18
未知
1 期
A phase I study of E7050 in subjects with solid tumorssolid tumor, gastric cancerJPRN-jRCT2080221558Eisai Co., Ltd.33
已完成
不适用
A phase 2a study of S-637880 in patients with neuropathic low back painjRCT2031200418Shionogi & Co., Ltd.160